---
title: "HYGIEIA GROUP released its interim results, with shareholders' profit attributable to shareholders reaching SGD 2.082 million, an increase of 90.66% year-on-year"
description: "HYGIEIA GROUP announced its interim results for the period ending June 30, 2025, with revenue of SGD 39.351 million, a year-on-year increase of 6.4%; profit attributable to shareholders was SGD 2.082 "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255052836.md"
published_at: "2025-08-28T15:36:03.000Z"
---

# HYGIEIA GROUP released its interim results, with shareholders' profit attributable to shareholders reaching SGD 2.082 million, an increase of 90.66% year-on-year

> HYGIEIA GROUP announced its interim results for the period ending June 30, 2025, with revenue of SGD 39.351 million, a year-on-year increase of 6.4%; profit attributable to shareholders was SGD 2.082 million, a year-on-year increase of 90.66%; earnings per share were 0.104 Singapore cents. The revenue growth was primarily driven by new large projects in Singapore and organic growth in environmental services in Thailand

According to the Zhitong Finance APP, HYGIEIA GROUP (01650) announced its interim results for the six months ending June 30, 2025, with revenue of SGD 39.351 million, an increase of 6.4% year-on-year; profit attributable to owners of the company was SGD 2.082 million, an increase of 90.66% year-on-year; earnings per share were 0.104 Singapore cents.

The announcement stated that the revenue growth was mainly due to large projects newly acquired in Singapore and the organic growth of the group's environmental services business in Thailand

### Related Stocks

- [01650.HK - HYGIEIA GROUP](https://longbridge.com/en/quote/01650.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Insilico Medicine Cayman TopCo 表示，公司与 Hygtia 达成了一项合作，价值超过 5 亿港元 | Insilico Medicine Cayman TopCo：CO 与 HYGTIA 达成合作，估值超过 5 亿港元，授予 HYGTIA 全球范围内对 ISM8969 的权利，符合条件的付款总额为 6600 万美元 | [Link](https://longbridge.com/en/news/273013562.md) |
| 今日交易——并购动态 | 1 月 13 日， Sino Biopharmaceutical 宣布以高达 12 亿元人民币（1.7204 亿美元）收购杭州海吉亚生物医药，以增强其慢性病治疗产品组合。Aware Super 收购了欧洲奥特莱斯购物中心合资企业 31.3% | [Link](https://longbridge.com/en/news/272399000.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.